HEBEI CHANGSHAN BIOCHEMICAL PHARMACEUTICAL CO., LTD.

Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

300255

CNE1000016C2

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-05-13 EDT			5-day change	1st Jan Change
11.2 ^CNY	+0.09%		-7.44%	-13.91%

04-28	Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-14	Yang Minghuan completed the acquisition of 5.8% stake in Hebei Changshan Biochemical Pharmaceutical Co., Ltd. from Gao Shuhua.	CI

Hebei Changshan Biochemical Pharmaceutical Co., Ltd.(XSEC:300255) added to S&P Global BMI Index

September 18, 2023 at 12:00 am

Latest news about Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-28	CI
Yang Minghuan completed the acquisition of 5.8% stake in Hebei Changshan Biochemical Pharmaceutical Co., Ltd. from Gao Shuhua.	03-13	CI
Yang Minghuan entered into an agreement to acquire 5.8% stake in Hebei Changshan Biochemical Pharmaceutical Co., Ltd. from Gao Shuhua for CNY 490 million.	02-23	CI
Hebei Changshan Biomedical Pharma's Controlling Shareholder to Sell 5.8% Company Stake	02-23	CI
Changshan Biochemical Pharmaceutical, Unit Get Nod to Trial Tumor Drug	01-09	MT
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-24	CI
Changshan Biochemical Pharmaceutical Gets Nod to Register Deep Vein Thrombosis Drug in Lebanon	23-10-19	MT
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.(XSEC:300255) added to S&P Global BMI Index	23-09-18	CI
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Changshan Biochemical Pharma Registers Enoxaparin Sodium Injection in Nicaragua	23-06-15	MT
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2022, Payable on June 27, 2023	23-05-17	CI
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2022	23-04-24	CI
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-21	CI
Changshan Biochemical Pharma’s Deep Vein Thrombosis Drug Shortlisted For China’s Drug Procurement Program	23-03-30	MT
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.(XSEC:300255) dropped from S&P Global BMI Index	22-12-19	CI
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Changshan Biochemical Wins Nod to Register Vein Thrombosis Drug in Turkmenistan	22-10-04	MT
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.(XSEC:300255) added to S&P Global BMI Index	22-09-19	CI
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-25	CI
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date Is 02 June 2022	22-05-25	CI
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Announces Cash Dividend for the Year 2021	22-05-12	CI
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Proposes Cash Dividend for the Year 2021	22-04-20	CI
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-19	CI

Chart Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

Duration

Period

Chart Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

More charts

Hebei Changshan Biochemical Pharmaceutical Co., Ltd is principally engaged in the research, development, manufacture and distribution of bio-pharmaceutical products. The Company primarily provides heparin product series. The Company provides sodium heparin active pharmaceutical ingredients (APIs) and hydro-acupuncture preparations. The Company's products are applied primarily in the prevention and treatment of cerebral vascular diseases, hardened arteries, myocardial infarction and phlebitis, among others. It distributes its products in domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-05-20 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
HEBEI CHANGSHAN BIOCHEMICAL PHARMACEUTICAL CO., LTD.	-13.91%	1.42B
CSL LIMITED	-1.26%	89.46B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.74B
BIOGEN INC.	-12.32%	33.03B
UCB	+54.12%	24.68B
BIOMARIN PHARMACEUTICAL INC.	-17.39%	15.12B
INCYTE CORPORATION	-9.14%	12.81B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-10.48%	11.79B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.45%	11.64B
SWEDISH ORPHAN BIOVITRUM AB	+7.19%	8.9B

Biopharmaceuticals